FDA approves Rasonque, a once-daily pill for advanced pancreatic cancer that nearly doubled median survival to 13.2 months in trials.
First targeting RAS tumor protein
From the August 26, 2026 GovBrief, every story that day in one place.
First targeting RAS tumor protein
From the August 26, 2026 GovBrief, every story that day in one place.